| Name | Title | Contact Details |
|---|
BioMedical Strategies is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chindex International, Inc. (Chindex) is engaged in the provision of healthcare services and the sale of medical equipment, instrumentation, and products in several healthcare markets in China, including Hong Kong. The Company operates in two business
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Inspire Medical Systems, Inc. has developed the world`s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient`s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Inspire therapy works inside your body, and with your natural breathing process. It might be right for you if you have been diagnosed with OSA, and can`t use or don`t get relief from CPAP/BiPAP.
Med South is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.